Efficacy and Tolerability of TENS in Endometriosis-related Pain

• Endometriosis is defined by the presence of endometrial tissue outside the uterine cavity. It affects 6% to 10% of women of childbearing age. Depending on its location, a distinction is made between superficial endometriosis, adenomyosis, and deep endometriosis. The potential mechanisms of endometriosis are still under discussion.
• Endometriosis is accompanied by a painful triad combining dysmenorrhea, dyspareunia, and chronic pelvic pain.
• Pain requires treatment due to its multiple impacts in terms of quality of life, anxiety, depression, loss of productivity at work, and absenteeism.
• Approximately one-third of women with endometriosis continue to suffer despite medical treatment.
• The pain of endometriosis is multifactorial, involving inflammatory, nociceptive, neuropathic, neurovascular, myofascial, and hormonal mechanisms. The recurrence of endometriosis-related pain means that it must be considered a chronic pain syndrome leading to peripheral and central neural sensitization. The intensity of the pain is not correlated with the severity of the disease.
• Transcutaneous electrical nerve stimulation (TENS) is a non-invasive, easy-to-use, well-tolerated, self-administered technique widely used for its analgesic effect in acute and chronic pain. Several studies have suggested the effectiveness of TENS in the management of pelvic pain related to endometriosis, but they are of uneven quality.
• Evaluating the effectiveness of TENS in the management of endometriosis-related pain under the best methodological conditions remains essential.

Inclusion criteria

• Women aged ≥ 18 years
• Endometriosis and/or adenomyosis diagnosed by imaging and/or histology
• Undergoing continuous, stable, and functional hormone treatment (with no menstruation) for at least 2 months
• No change in hormone treatment planned for the duration of the study
• Chronic pelvic pain for more than 6 months
• Pelvic pain at least equal to 2 out of 3 (on the intensity scale: "0 - None," "1 - Mild," "2 - Moderate," "3 - Severe")
• Agreeing to participate in the study
• Agrees to limit pain relief treatment during the study to level I painkillers paracetamol and Acupan® (nefopam), and the NSAID Antadys® (flurbiprofen)
• Has a computer, tablet, or cell phone with an internet connection
• Is affiliated with a social security system or is a beneficiary of such a system

Exclusion criteria

• Pregnant or breastfeeding women
• Menopausal women
• Patients who, in the investigator's opinion, have experienced an acute worsening of endometriosis symptoms in the last 28 days
• Patients with altered sensitivity in the area where the device is applied (hypoesthesia)
• Skin allergy to the gel or electrodes
• Dermatological problem in the stimulation area
• Patients with an implanted pacemaker or active implanted medical device.
• Epilepsy
• Current thrombophlebitis or arterial thrombosis
• Cancer or malignant disease with an expected survival of < 12 months
• Alcoholism or drug addiction
• Fibromyalgia
• Women who have already tried TENS
• Patients unable to understand and use the English language to communicate fluently
• Patients with cognitive impairments
• Untreated severe psychiatric illness and/or psychological condition that is the primary determinant of the patient's condition
• Participation in another intervention study that may impact the results of the current study
• Patient using > 90 morphine equivalents/day (at least once in the last 28 days)
• Gynecological and/or endometriosis surgery planned within the next 3 months
• History of endometriosis surgery within the last 6 months
• Patient who has undergone a hysterectomy or bilateral oophorectomy
• Patient under legal protection (guardianship or conservatorship) or patient deprived of liberty